Department of Internal Medicine Number 2, Bogomolets National Medical University, Kyiv, Ukraine.
J Int Med Res. 2022 Jun;50(6):3000605221103959. doi: 10.1177/03000605221103959.
Effective prevention of thromboembolism is essential for patients with mechanical prosthetic heart valves. For this group of patients, vitamin K antagonists (VKAs) remain the drug group of choice despite the widespread use of new anticoagulants in other diseases. As a consequence, warfarin resistance remains a serious challenge for physicians. The current report describes a 65-year-old male patient that had a mechanical prosthetic aortic valve implanted due to severe aortic insufficiency after infective endocarditis. Despite consistent increases in his warfarin dose, the level of international normalized ratio (INR) remained very low. The patient was considered to have warfarin resistance. Warfarin was successfully replaced by another VKA, acenocoumarol, which resulted in a stable INR observed over 1 year of follow-up. Achieving the target INR in patients with mechanical prosthetic heart valves using VKAs is the main goal of thromboprophylaxis. Although the genetic changes that cause warfarin resistance are understood, the options to overcome these pharmacogenetic issues remain limited. Based on the success with this current patient, physicians with similar patients with warfarin resistance might wish to consider replacing warfarin with acenocoumarol.
对于机械心脏瓣膜置换患者而言,有效的血栓栓塞预防至关重要。尽管新型抗凝剂在其他疾病中的应用已较为广泛,但对于该类患者,维生素 K 拮抗剂(VKA)依然是首选药物。因此,华法林抵抗仍然是医生面临的一大挑战。本报告介绍了一位 65 岁男性患者,因感染性心内膜炎后严重主动脉瓣关闭不全而植入机械性主动脉瓣。尽管持续增加华法林剂量,但国际标准化比值(INR)仍非常低。该患者被认为存在华法林抵抗。华法林成功被另一种 VKA,即醋硝香豆素替代,在 1 年的随访中观察到 INR 稳定。使用 VKA 使机械心脏瓣膜置换患者达到目标 INR 是血栓预防的主要目标。尽管导致华法林抵抗的遗传变化已被理解,但克服这些药物遗传学问题的选择仍然有限。基于当前患者的成功,对于存在华法林抵抗的类似患者,医生可能希望考虑用醋硝香豆素来替代华法林。